Japan Unit Of AstraZeneca Begins Second-Phase Trials For Lupus Drug
This article was originally published in PharmAsia News
Executive Summary
The Japanese unit of U.K.-based AstraZeneca says it has begun Phase II trials of its MEDI-545 (sifalimumab) drug for treating lupus. The treatment being tested by AstraZeneca KK relies on supplying an antibody for interferon alpha considered to be the cause of lupus in high concentrations. Another AstraZeneca subsidiary, U.S.-based Medimmune, created the drug in 2004 and is developing it through its subsidiaries in Japan, Europe and the United States. (Click here for more - a subscription may be required
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.